Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 20/20 | 0.70 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.70 |
| ▸ | MAOA | P21397 | 3/20 | 0.65 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA4 | P22748 | 1/20 | 0.59 |
| ▸ | CA5A | P35218 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5656236 | 1.00 | MAOB (0.70) | MAOBADORA2BMAOACA12CA1 | |
| SCHEMBL4973439 | 0.83 | MAOB (1.00) | MAOBADORA2BMAOA | |
| SCHEMBL4972722 | 0.80 | MAOB (1.00) | MAOBADORA2BMAOACA12CA1 | |
| SCHEMBL5655981 | 0.77 | MAOB (0.67) | MAOBADORA2BMAOACA12CA1 | |
| SCHEMBL31661723 | 0.77 | MAOB (0.67) | MAOBADORA2BMAOACA12CA1 | |
| SCHEMBL5656232 | 0.76 | MAOB (0.70) | MAOBMAOACA12CA1CA2 | |
| SCHEMBL6381563 | 0.74 | ALOX15 (0.70) | — | |
| SCHEMBL13593291 | 0.74 | PLG (0.67) | — | |
| SCHEMBL4969164 | 0.74 | MAOB (1.00) | MAOBADORA2BMAOA | |
| SCHEMBL10102714 | 0.74 | NR1H4 (0.72) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | disclosed |